DBV Technologies (NASDAQ:DBVT) Shares Set to Reverse Split on Friday, November 29th

DBV Technologies S.A. (NASDAQ:DBVT) shares are going to reverse split on the morning of Friday, November 29th. The 1-5 reverse split was announced on Monday, November 11th. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, November 28th.

DBV Technologies Stock Performance

NASDAQ:DBVT opened at $0.63 on Wednesday. The stock has a 50-day simple moving average of $0.74 and a two-hundred day simple moving average of $0.90. The firm has a market capitalization of $61.18 million, a PE ratio of -0.75 and a beta of 0.66. DBV Technologies has a 52-week low of $0.50 and a 52-week high of $2.14.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on DBVT shares. HC Wainwright boosted their price objective on DBV Technologies from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Thursday, October 24th. JMP Securities reiterated a “market outperform” rating and issued a $5.00 price target on shares of DBV Technologies in a research report on Tuesday, September 24th. Finally, StockNews.com initiated coverage on shares of DBV Technologies in a research report on Wednesday, November 6th. They set a “hold” rating on the stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. lifted its stake in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,568,909 shares of the company’s stock after buying an additional 327,345 shares during the quarter. DBV Technologies makes up about 0.2% of Yiheng Capital Management L.P.’s investment portfolio, making the stock its 15th largest position. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 as of its most recent filing with the SEC. 71.74% of the stock is owned by institutional investors and hedge funds.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.